MSMichael R. Stratton

Michael R. Stratton

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Recognitions

Top Cited Scholar (2024,2025,2026)

Michael R. Stratton has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Convergent mutational processes in esophageal and junctional adenocarcinomas across eight countries

    by Laura Torrens, Sarah Moody, Jiali Pang, Behnoush Abedi-Ardekani, Haoran Zhang, Ammal Abbasi, Charles Nunn, Stephen Fitzgerald, Pilar Gallego-García, Valerie Gaborieau, et al.

    The incidence distribution of esophageal adenocarcinoma (EAC) and gastroesophageal junction (GEJ) cancers presents important geographic variations, yet the causes of these differences remain unclear. We analyzed 520 whole genomes from EAC/GEJ tumors across eight countries to examine the mutational forces shaping these cancers and their geographic variation. The mutational landscape was highly similar between EAC and GEJ tumors, and was dominated by signatures SBS17a/b, previously associated with reflux in EAC/GEJ. SBS17a/b were linked to obesity in EAC, supporting an indirect role in exacerbating reflux-mediated mutagenesis. Other established risk factors, such as tobacco smoking, did not yield a direct mutational footprint, pointing to non-mutagenic effects in EAC/GEJ. Nonetheless, geographic differences were present, with signatures related to endogenous cellular functions enriched in high-incidence populations. These findings provide new insights into the shared mutational forces that shape EAC and GEJ, as well as their geographic distribution.

  • Open Access

    Mutational signature landscape of pancreatic cancer genomes from nine countries

    by Sarah Moody, Thomas Cattiaux, Jiali Pang, Haoran Zhang, Charles Nunn, Stephen Fitzgerald, Pilar Gallego-Garcia, Priscilia Chopard, Arash Nikmanesh, Valerie Gaborieau, et al.

    Approximately half of all pancreatic cancers cannot be explained by known risk factors. Here we present the results of mutational signature analysis in 495 cases of pancreatic cancer from nine countries to explore whether there are previously unknown mutagenic exposures acting on pancreatic cancer genomes. The mutational signature landscape was consistent between countries. We identified one signature not previously found in pancreatic cancer, SBS111, which does not have a confirmed aetiology but is present in >99% of cases and contributes on average 26% of the total mutation burden. No evidence was found for mutational signatures known to be caused by exogenous exposures, nor was any mutational signature capable of explaining differences in incidence rates between countries. These results suggest that the unexplained causes of pancreatic cancer are unlikely to be strongly mutagenic and that non-mutagenic mechanisms may have a prominent role in explaining pancreatic cancer incidence.

  • Open Access

    Identification and validation of a previously missed mutational signature in colorectal cancer

    by Mariya Kazachkova, Burçak Otlu, Marcos Díaz-Gay, Ammal Abbasi, Sarah Moody, Zichen Jiang, Sandra Perdomo, David. C. Wedge, Paul Brennan, Michael. R. Stratton, et al.

    Mutational signature analysis has enhanced our understanding of mutagenic processes. In a recent study, we analyzed 802 microsatellite-stable colorectal cancers (CRC) and identified a de novo signature, SBS_D, which was decomposed into SBS18. Here, we re-evaluate this decomposition and provide evidence that SBS_D represents a distinct mutational process from SBS18. Through an analysis of 2,616 CRCs across three independent cohorts, we demonstrate that SBS_D is consistently present, suggesting this signature may have been previously overlooked. We illustrate that the pattern of SBS_D better aligns with signatures associated with deficiencies in DNA repair, despite evidence that SBS_D is not driven by canonical defects in these DNA repair pathways. Overall, this study identifies a previously unrecognized mutational signature in DNA repair-proficient CRC and proposes that its etiology may be linked to DNA repair infidelity emerging late in tumor development. SBS_D has been submitted to the COSMIC database and provisionally designated as SBS111.


  • Top Cited Papers
    Open Access

    A tumour-derived organoid biobank maps cancer gene dependencies

    by C. Herranz-Ors, S. G. Bhosle, A. E. Beck, J. G. R. Gilbert, G. Picco, J. Espejo Valle-Inclan, F. Muyas, S. Valentini, A. E. Andres, R. Ansari, et al.

    Cancer cell lines remain foundational for research and drug discovery, yet they incompletely capture tumour diversity, lack linked patient context, and have undergone adaptation to culture. Tumour organoids are three-dimensional cultures derived from patient tissue that offer a powerful complement to cell lines 1 . Here we derived and characterized 256 clinically annotated tumour organoids directly from colorectal, oesophageal, ovarian, pancreatic and gastric cancers as renewable, genetically stable models. Extensive characterization of each model and matched patient tumour samples included whole-genome and transcriptome sequencing, and genome-wide CRISPR–Cas9 screens across 162 organoids mapped gene dependencies. Integrative analyses revealed genomic and clinical markers of dependency across common and rare subtypes, identified organoid-specific essential genes, and revealed targetable vulnerabilities following tumour evolution in paired pre- and post-treatment samples. In colorectal cancer, functional and pharmacological interrogation of the EGFR–RAS–MAPK axis uncovered differential effects of KRAS variant alleles. This open, publicly available resource provides a systematic map of gene dependencies in patient-derived organoids, expanding the model diversity and mechanistic insight needed to advance precision oncology.


  • Top Cited Papers
    Open Access

    Polyclonal selection of immune checkpoint mutations in thyroid autoimmunity

    by Pantelis A. Nicola, Andrew R. J. Lawson, Alexandra Tidd, Juliette Imbert, Yoshihiro Ishida, Luke A. Wylie, Paul A. Scott, Kenny Roberts, Luke M. R. Harvey, Stefanie V. Lensing, et al.

    Our immune system contains multiple checkpoints to prevent the activation of self-reactive lymphocytes. How some lymphocytes escape these constraints to cause autoimmune disease remains poorly understood. A long-standing hypothesis posits that somatic mutations in immune regulatory genes may enable self-reactive lymphocytes to bypass tolerance checkpoints 1–3 , but testing this has been challenging owing to technical limitations. Here we used whole-exome and targeted NanoSeq 4,5 , an accurate single-molecule DNA sequencing protocol, to comprehensively search for driver mutations in autoimmune thyroid disease. This showed many B cell clones convergently acquiring loss-of-function mutations in the key immune checkpoint genes TNFRSF14 (also known as HVEM ) and CD274 (which encodes PD-L1), as well as less frequent mutations in other immune genes. In highly inflamed biopsies, we detected tens to hundreds of independent immune checkpoint mutant clones. Laser microdissection, methylation sequencing, spatial transcriptomics, immunostaining, single-nucleus DNA sequencing and antibody synthesis localized these mutations to B cells, confirmed some to be self-reactive and identified clones carrying multiple hits. We found widespread TNFRSF14 biallelic loss, and clones with as many as 4–6 driver mutations. While each clone accounts for a small fraction of cells (typically less than 1%), the myriad mutant clones in each donor amounted to a substantial fraction of B cells harbouring driver mutations. Our results support the hypothesis that somatic mutations in autoimmune lymphocytes may allow them to escape tolerance constraints through a polyclonal cascade of somatic evolution, providing insights into the molecular basis of autoimmune disease.


  • Open Access

    Systemic mutagen exposures reported by normal kidney cell genomes

    by Yichen Wang, William Knight, Aida Ferreiro-Iglesias, Behnoush Abedi-Ardekani, My H. Pham, Sarah Moody, Yvette Hooks, Federico Abascal, Charles Nunn, Stephen Fitzgerald, et al.

    Lifestyle, environmental and other exposures to exogenous mutagens generate somatic mutations in normal human cells in vivo and increase cancer risk. However, the global repertoire of exogenous mutagen exposures is uncertain. The mutational signatures of mutagens in normal tissues offer opportunities to detect such exposures and survey them at population level. Using single-molecule duplex sequencing of normal kidney (n=319) and blood (n=272) samples from 10 countries, we show that normal kidney cell genomes report an extensive repertoire of somatic mutational signatures. Microdissection of kidney structures revealed that proximal tubules exhibit higher mutation rates than other components of the nephron and most normal cell types despite low cell division rates. This is explained by marked enrichment of mutational signatures due to known exogenous carcinogenic mutagens including the plant-derived aristolochic acids, as well as several signatures of unknown causes including an unknown agent prevalent in Japan (SBS12), and signatures of uncertain origins (SBS40b and SBS40c). The results suggest the existence of multiple, common, systemically circulating mutagens affecting human populations and indicate that the genomes of kidney proximal tubule cells report such exposures with high sensitivity.


  • Early-Life Mutagenesis and the Rise of Early-Onset Colorectal Cancer

    by Ludmil B. Alexandrov, Paul Brennan, Michael R. Stratton

    Summary: Colorectal cancer incidence is rising globally among individuals younger than 50 years and remains poorly explained by established risk factors. In this study, we advance the hypothesis that early-childhood exposure to mutagen-producing bacteria contributes to lifetime colorectal cancer risk by imprinting oncogenic mutations in the developing colorectal epithelium, thereby initiating tumorigenesis decades before clinical diagnosis and redefining early-onset colorectal cancer as a disease rooted in early-life mutagenic exposure.


  • Open Access

    Sperm sequencing reveals extensive positive selection in the male germline

    by Matthew D. C. Neville, Andrew R. J. Lawson, Rashesh Sanghvi, Federico Abascal, My H. Pham, Alex Cagan, Pantelis A. Nicola, Tetyana Bayzetinova, Adrian Baez-Ortega, Kirsty Roberts, et al.

    Mutations that occur in the cell lineages of sperm or eggs can be transmitted to offspring. In humans, positive selection of driver mutations during spermatogenesis can increase the birth prevalence of certain developmental disorders 1–3 . Until recently, characterizing the extent of this selection in sperm has been limited by the error rates of sequencing technologies. Here we used the duplex sequencing method NanoSeq 4 to sequence 81 bulk sperm samples from individuals aged 24–75 years. Our findings revealed a linear accumulation of 1.67 (95% confidence interval of 1.41–1.92) mutations per year per haploid genome driven by two mutational signatures associated with human ageing. Deep targeted and exome NanoSeq 5 of sperm samples identified more than 35,000 germline coding mutations. We detected 40 genes (31 newly identified) under significant positive selection in the male germline that have activating or loss-of-function mechanisms and are involved in diverse cellular pathways. Most of the positively selected genes are associated with developmental or cancer predisposition disorders in children, whereas four of the genes exhibited increased frequencies of protein-truncating variants in healthy populations. We show that positive selection during spermatogenesis drives a 2–3-fold increased risk of known disease-causing mutations, which results in 3–5% of sperm from middle-aged to older individuals with a pathogenic mutation across the exome. These findings shed light on germline selection dynamics and highlight a broader increased disease risk for children born to fathers of advanced age than previously appreciated.


  • Top Cited Papers
    Open Access

    Somatic mutation and selection at population scale

    by Andrew R. J. Lawson, Federico Abascal, Pantelis A. Nicola, Stefanie V. Lensing, Amy L. Roberts, Georgios Kalantzis, Adrian Baez-Ortega, Natalia Brzozowska, Julia S. El-Sayed Moustafa, Dovile Vaitkute, et al.

    As we age, many tissues become colonized by microscopic clones carrying somatic driver mutations 1–7 . Some of these clones represent a first step towards cancer whereas others may contribute to ageing and other diseases. However, our understanding of this phenomenon remains limited due to the challenge of detecting mutations in small clones. Here we introduce a new version of nanorate sequencing (NanoSeq) 8 , a duplex sequencing method with an error rate lower than five errors per billion base pairs, which is compatible with whole-exome and targeted capture. Deep sequencing of polyclonal samples with single-molecule sensitivity simultaneously profiles large numbers of clones, providing accurate mutation rates, signatures and driver frequencies in any tissue. Applying targeted NanoSeq to 1,042 non-invasive samples of oral epithelium and 371 blood samples from a twin cohort, we report an extremely rich selection landscape, with 46 genes under positive selection in oral epithelium, more than 62,000 driver mutations and evidence of negative selection in essential genes. High-resolution maps of selection across coding and non-coding sites are obtained for many genes: a form of in vivo saturation mutagenesis. Multivariate regression models enable mutational epidemiology studies on how exposures and cancer risk factors, such as age, tobacco or alcohol, alter the acquisition or selection of somatic mutations. Accurate single-molecule sequencing provides a powerful tool to study early carcinogenesis, cancer prevention and the role of somatic mutations in ageing and disease.


  • Open Access

    Author Correction: The long-term effects of chemotherapy on normal blood cells

    by Emily Mitchell, My H. Pham, Anna Clay, Rashesh Sanghvi, Nicholas Williams, Sandra Pietsch, Joanne I. Hsu, Nina Friesgaard Øbro, Hyunchul Jung, Aditi Vedi, et al.